Last reviewed · How we verify
NEXOBRID (ANACAULASE-BCDB)
NEXOBRID (generic name: ANACAULASE-BCDB) is a drug developed by MEDIWOUND, LTD. It is currently FDA-approved for Removal of escars from deep thermal burn.
NexoBrid is an enzyme-based treatment used for the removal of necrotic tissue. It is being studied for the treatment of acute deep partial and full thickness burn injuries.
At a glance
| Generic name | ANACAULASE-BCDB |
|---|---|
| Sponsor | MEDIWOUND, LTD |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Removal of escars from deep thermal burn
Common side effects
- Pruritus
- Pyrexia
Serious adverse events
- Anaphylaxis
- Hypersensitivity
- Urticaria
Key clinical trials
- A Multicenter, Prospective, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of Venous Leg Ulcers (VALUE (Phase 3)
- Use of NexoBrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries (N/A)
- A Multicenter, Multinational, Randomized, Controlled, Assessor Blinded Study, Performed in Subjects With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid Compared to Gel Vehicle and Comp (Phase 3)
- A Multicenter, Prospective, Randomized, Placebo and Collagenase (Non-surgical Standard-of-care) Controlled Study, Performed to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Form (Phase 2)
- A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NEXOBRID CI brief — competitive landscape report
- NEXOBRID updates RSS · CI watch RSS
- MEDIWOUND, LTD portfolio CI
Frequently asked questions about NEXOBRID
What is NEXOBRID?
What is NEXOBRID used for?
Who makes NEXOBRID?
What is the generic name of NEXOBRID?
What development phase is NEXOBRID in?
What are the side effects of NEXOBRID?
Related
- Manufacturer: MEDIWOUND, LTD — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Removal of escars from deep thermal burn
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing